摘要:
A nanostructure is described. The nanostructure includes a nanoparticle, a shell encompassing the nanoparticle, and a gap having a width ranging from 1.0 nm to 6.0 nm and located between the nanoparticle and the shell to enable the nanostructure to generate a fluorescence.
摘要:
The present invention is related to a composition of PI3K inhibitor, comprising: 0.01˜10 mg of PI3K inhibitor; 10˜500 mg of poly(lactic-co-glycolic acid) (PLGA) which is encapsulated onto the surface of the PI3K inhibitor and the surface is non-modified by a modifier; and the composition has a size of 10˜1000 nm. Thereby, an excellent effect on suppressing the growth of tumor cells will be achieved by the encapsulation of PI3K inhibitor into PLGA nanomaterials without any modifier on its surface, the optimization of a ratio of PI3K inhibitor to PLGA, and the accordingly slow release of the composition.
摘要:
A phosphate-containing nanoparticle delivery vehicle includes nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.
摘要:
The present invention relates to a process for preparing water-soluble and dispersed iron oxide (Fe3O4) nanoparticles and application thereof, characterized in which two-stage additions of protective agent and chemical co-precipitation are employed in the process. In the first stage, Fe3O4 nanoparticles are obtained using absorbent-reactant coexistence technology. In the second stage, proper amount of adherent is added to cover the nanoparticle surface entirely. The resulting water-soluble and dispersed Fe3O4 nanoparticles can easily bind with thiols or biomolecules, such as nucleic acid and peptide. The Fe3O4 nanoparticles of the present invention may be used as magnetic resonance imaging contrast agent and used in magnetic guiding related biomolecular technologies for clinical testing, diagnosis and treatment.
摘要翻译:本发明涉及一种制备水溶性和分散的氧化铁(Fe 3 O 4)纳米颗粒的方法及其应用,其特征在于在该过程中采用两步添加保护剂和化学共沉淀。 在第一阶段,使用吸收剂 - 反应物共存技术获得Fe3O4纳米颗粒。 在第二阶段,添加适量的粘附剂以完全覆盖纳米颗粒表面。 所得到的水溶性和分散的Fe 3 O 4纳米颗粒可以容易地与硫醇或生物分子如核酸和肽结合。 本发明的Fe 3 O 4纳米颗粒可用作磁共振成像造影剂,用于磁导相关的生物分子技术用于临床测试,诊断和治疗。
摘要:
The present invention relates to a process for preparing water-soluble and dispersed iron oxide (Fe3O4) nanoparticles and application thereof, characterized in which two-stage additions of protective agent and chemical co-precipitation are employed in the process. In the first stage, Fe3O4 nanoparticles are obtained using absorbent-reactant coexistence technology. In the second stage, proper amount of adherent is added to cover the nanoparticle surface entirely. The resulting water-soluble and dispersed Fe3O4 nanoparticles can easily bind with thiols or biomolecules, such as nucleic acid and peptide. The Fe3O4 nanoparticles of the present invention may be used as magnetic resonance imaging contrast agent and used in magnetic guiding related biomolecular technologies for clinical testing, diagnosis and treatment.
摘要翻译:本发明涉及一种制备水溶性和分散的氧化铁(Fe 3 O 4 O 4)纳米颗粒的方法及其应用,其特征在于两步加入保护性 代谢和化学共沉淀在该过程中被采用。 在第一阶段,使用吸收剂 - 反应物共存技术获得Fe 3 O 4 O 4纳米颗粒。 在第二阶段,添加适量的粘附剂以完全覆盖纳米颗粒表面。 所得到的水溶性和分散的Fe 3 O 4纳米颗粒可以容易地与硫醇或生物分子如核酸和肽结合。 本发明的Fe 3 N 4 O 4纳米颗粒可用作磁共振成像造影剂,并用于磁导向相关生物分子技术用于临床测试,诊断和治疗。
摘要:
The present invention relates to a nano-carrier for an anticancer drug, which comprises: a metal nanoparticle; and a polynucleotide for connecting with an anticancer drug having a pyrimidine group or a purine group, wherein the polynucleotide connects to a surface of the metal nanoparticle, and the anticancer drug binds to the polynucleotide through the pyrimidine group or the purine group. In addition, the present invention also provides a complex of an anticancer drug and a nano-carrier, a pharmaceutical composition thereof, a method for manufacturing the complex, and a method for treating a cancer by using the pharmaceutical composition.
摘要:
A phosphate-containing nanoparticle delivery vehicle includes a nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.
摘要:
A phosphate-containing nanoparticle delivery vehicle includes a nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.
摘要:
A phosphate-containing nanoparticle delivery vehicle includes a nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.
摘要:
A phosphate-containing nanoparticle delivery vehicle includes nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.